Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

STRIDES PHARMA SCIENCE LIMITED Capital/Financing Update 2024

Jan 11, 2024

62616_rns_2024-01-11_5c8cc4f7-45c0-464d-ae38-f87ef9b9305d.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

==> picture [145 x 48] intentionally omitted <==

January 11, 2024

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

Scrip code: 532531

The National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex Bandra (E) Mumbai - 400 051

Scrip code: STAR

Dear Madam/ Sir,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/ HO/ CFD/ CFD-PoD-1/ P/ CIR/ 2023/ 123 dated July 13, 2023

This is to inform you that as part of entity optimization exercise, Fairmed Healthcare AG, Switzerland, a step-down subsidiary of the Company in Switzerland, has entered into a Share Purchase Agreement dated January 9, 2024, for divestment of its 100% shareholding in Eris Pharma GmbH, Germany (Eris) to a third party.

Disclosure under Regulation 30 of SEBI Listing Regulations read with SEBI Circular dated July 13, 2023 relating to the proposed transaction is enclosed.

This is for your information and records.

Thanks & Regards, For Strides Pharma Science Limited, Digitally signed by MANJULA R MANJULA R Date: 2024.01.11 15:13:10 +05'30' Manjula Ramamurthy Company Secretary ICSI Membership No. A30515

==> picture [92 x 89] intentionally omitted <==

Encl. As above

==> picture [480 x 53] intentionally omitted <==

==> picture [145 x 48] intentionally omitted <==

Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with SEBI/ HO/ CFD/ CFD-PoD-1/ P/ CIR/ 2023/ 123 dated July 13, 2023

Divestment of 100% stake in Eris Pharma GmbH, Germany by Fairmed Healthcare AG, Switzerland, a step-down subsidiary of the Company

# Particulars Remarks
a) Amount and percentage of
Turnover or Revenue or Income and net
worth contributed by such unit or division
or undertaking or subsidiary or associate
company of the listed entity during the last
financial year
The transaction relates to sale of 100%
shareholding held in Eris Pharma GmbH, Germany
(Eris) by Fairmed Healthcare AG, Switzerland
(Fairmed), a step-down subsidiary of the Company.
Eris’ revenue for FY23 was ~Euro 5,062 and had a
negative networth.
b) Date on which Agreement for Sale has
been entered into
January 9, 2024
c) Expected Date of Completion of Sale/
Disposal
Closing shall take place on or before
January 31, 2024 OR any other date as mutually
agreed between the parties.
d) Consideration received from such Sale/
Disposal
Euro 200,000
e) Brief details of Buyers and
Whether any of the Buyers belong to
Promoter/ Promoter Group/ Group
companies.
If yes, details thereof
Maxmind Pharmaceutical SL having its registered
office at Calle Copenhague 12, Oficina 205,
Edificio Tifan, Las Rozas de Madrid 28232, Spain.
Buyer is not related to any of the Promoter/
Promoter Group/ Group Companies of Strides.
f) Whether transaction would fall within
Related Party Transactions?
If yes, whether the same is done at “Arms’
length”;
No

==> picture [480 x 133] intentionally omitted <==

==> picture [145 x 48] intentionally omitted <==

g) Whether sale, lease or disposal of the
undertaking is outside Scheme of
Arrangement?
If yes, details of the same including
compliance with regulation 37A of LODR
Regulations
Not Applicable
h) Additionally, in case of a slump sale,
indicative disclosures provided for
amalgamation/ merger, shall be disclosed
by the listed entity with respect to such
slump sale.
For the purpose of this sub-clause, "slump
sale" shall mean the transfer of one or
more undertakings, as a result of the sale
for a lump sum consideration, without
values being assigned to the individual
assets and liabilities in such sales.
Not Applicable
i) Reason for delay in intimation While the Company had sought certain
clarifications from the concerned parties, receipt of
such clarification was delayed.
Consequently, intimation for this transaction to
Stock Exchanges is delayed by one day.

==> picture [92 x 89] intentionally omitted <==

==> picture [480 x 53] intentionally omitted <==